Early lipid changes with atazanavir/ritonavir or darunavir/ritonavirE Martinez, Ana Gonzalez‐Cordón, Elena Ferrer et al.|HIV Medicine|2014Cited by 32
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna Gonzalez‐Cordón, Juergen Rockstroh, Lambert Assoumou et al.|Journal of Antimicrobial Chemotherapy|2021Cited by 27
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Luminita Schneider, Lambert Assoumou et al.|Clinical Infectious Diseases|2022Cited by 17
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE TrialCarl J. Fichtenbaum, Dushyantha Jayaweera, Judith S. Currier et al.|The Journal of Infectious Diseases|2020Cited by 13
Metabolic effects of atazanavir/ritonavir vs darunavir/ritonavir in combination with tenofovir/emtricitabine in antiretroviral‐naïve patients (ATADAR Study)Estebán Martínez, Ana Gonzalez‐Cordón, Daniel Podzamczer et al.|Journal of the International AIDS Society|2012Cited by 4